Literature DB >> 8332139

Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons.

S M Chou1, F H Norris.   

Abstract

Contrary to the recently reemphasized notion that the primary neuron involved in amyotrophic lateral sclerosis (ALS) is the cortical (upper) motor neuron (UMN), we believe that the lower motor neuron (LMN) is primarily involved by the retrograde transport of pathogens from neuromuscular junctions, and the disease process spreads monosynaptically to the UMN. Pathologically and epidemiologically, the LMN hypothesis is more logical than the UMN in light of the recent understanding of neuroaxonal transport systems, particularly in regard to anterograde cytoskeleton transport and the kinetics of the force promoting slow axonal transport. By correlating the early pathologic findings, i.e., the swelling of the initial axons and formation of intracytoplasmic inclusions in the LMN, ALS may be regarded as a disease of axonal transport, especially its slow component (SCa). Therapeutic intervention to facilitate SCa should be attempted in ALS.

Entities:  

Mesh:

Year:  1993        PMID: 8332139     DOI: 10.1002/mus.880160810

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  34 in total

1.  Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis.

Authors:  N Filippini; G Douaud; C E Mackay; S Knight; K Talbot; M R Turner
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

Review 2.  ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration.

Authors:  John M Ravits; Albert R La Spada
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

Review 3.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 4.  Presymptomatic studies in ALS: rationale, challenges, and approach.

Authors:  Michael Benatar; Joanne Wuu
Journal:  Neurology       Date:  2012-10-16       Impact factor: 9.910

Review 5.  Brain-computer interfaces for communication and rehabilitation.

Authors:  Ujwal Chaudhary; Niels Birbaumer; Ander Ramos-Murguialday
Journal:  Nat Rev Neurol       Date:  2016-08-19       Impact factor: 42.937

6.  Changes in the Excitability of Neocortical Neurons in a Mouse Model of Amyotrophic Lateral Sclerosis Are Not Specific to Corticospinal Neurons and Are Modulated by Advancing Disease.

Authors:  Juhyun Kim; Ethan G Hughes; Ashwin S Shetty; Paola Arlotta; Loyal A Goff; Dwight E Bergles; Solange P Brown
Journal:  J Neurosci       Date:  2017-08-17       Impact factor: 6.167

7.  Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.

Authors:  Arianna Sala; Leonardo Iaccarino; Piercarlo Fania; Emilia G Vanoli; Federico Fallanca; Caterina Pagnini; Chiara Cerami; Andrea Calvo; Antonio Canosa; Marco Pagani; Adriano Chiò; Angelina Cistaro; Daniela Perani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-07       Impact factor: 9.236

Review 8.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 9.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression.

Authors:  Josiah J Herzog; Weijin Xu; Mugdha Deshpande; Reazur Rahman; Hannah Suib; Avital A Rodal; Michael Rosbash; Suzanne Paradis
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.